Lumida
/KALV
⌘K
Kalvista Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

KALV
$27.00USD+0.04%+0.01 today

MARKET CAP

1.4B

P/E (TTM)

FWD P/E

DAY RANGE

$27 – $27

52W RANGE

$10
$27

AI Summary

Stalk
StalkMedium

KALV remains in a Stage 2 advancing regime underpinned by a strong parabolic acceleration, reinforcing a bullish medium-term bias. However, price is severely extended above rising short-term EMAs with RSI and Options Score in extreme overbought territory, signaling near-term exhaustion risk. Execution should be deferred and staged on meaningful pullbacks into the rising EMA zone or the recent breakout support area.

  • Ectorly launch generated $1.4M net revenue in Q1, capturing 5% of U.S. HAE prescriptions
  • FDA-approved oral on-demand therapy with pediatric NDA filing planned after positive Phase 3 interim data
  • Q1 operating expenses totalled $60.4M, including $15M in R&D and SG&A costs
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2017FY 2018FY 2019FY 2020TREND
Sales, Adj.$1.5M$8.4M$16.1M$12.7M
YoY %+458.1%+92.1%-21.3%
P / Sales22.4x11.8x21.5x15.3x
EV / Sales3.8x9.8x20.8x14.7x
Gross Profit, Adj.$1.5M$8.4M$16.1M$12.7M
YoY %+458.1%+92.1%-21.3%
Margin %100.0%100.0%100.0%100.0%
EV / Gross Profit3.8x9.8x20.8x14.7x
EBITDA, Adj.$-22.3M$-18.5M$-29.4M$-40.0M
YoY %+16.9%-58.9%-35.9%
Margin %-1482.6%-220.7%-182.6%-315.4%
EV / EBITDA-0.3x-4.4x-11.4x-4.7x
EBIT$-22.3M$-18.7M$-29.8M$-40.5M
YoY %+16.3%-59.4%-35.9%
Margin %-1485.3%-222.8%-184.9%-319.4%
EV / EBIT-0.3x-4.4x-11.3x-4.6x
Net Income$-20.8M$-15.8M$-20.8M$-29.1M
YoY %+23.9%-31.7%-39.9%
Net Margin-1381.3%-188.3%-129.1%-229.4%
EPS (GAAP)-$4.47-$1.53-$1.38-$1.64
YoY %+65.8%+9.8%-18.8%